Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges

被引：0

作者：

Chen, Tong ^{[1
]}

Liu, Fang ^{[1
]}

机构：

[1] Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China

来源：

LUNG CANCER | 2025年 / 204卷

关键词：

NSCLC; Neoadjuvant immunotherapy; Immune checkpoint inhibitors; Tumor microenvironment; Biomarkers; Multicohomology; CELL LUNG-CANCER; MOLECULAR RESIDUAL DISEASE; SINGLE-ARM; OPEN-LABEL; PATHOLOGICAL RESPONSE; PLUS CHEMOTHERAPY; EFFICACY; MULTICENTER; TRIAL; IMMUNOCHEMOTHERAPY;

D O I：

10.1016/j.lungcan.2025.108588

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neoadjuvant immunotherapy has shown impressive outcomes in treating non-small cell lung cancer (NSCLC) recently due to advancements in immune checkpoint inhibitors (ICIs) research. Neoadjuvant immunotherapy can lower the tumor load, raise the complete surgical (R0) resection rate, and improve clinical outcomes by alleviating the immune system repression caused by tumor cells. This review provides a comprehensive evaluation of neoadjuvant immunotherapy in NSCLC, focusing on: (1) its safety and efficacy profiles, (2) the most recent clinical trial evidence, and (3) critical unresolved challenges including predictive biomarker development, management of driver mutation-positive patients, chronic obstructive pulmonary disease (COPD) comorbidity considerations, and its application in stage III-IVA (oligometastatic) disease. Furthermore, we explore future research directions to optimize neoadjuvant immunotherapy approaches for resectable NSCLC, aiming to guide clinical practice and investigation.

引用

页数：11

共 90 条

[51]

Research C for DE, 2024, FDA

[52]

Research C for DE, 2024, FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer

[53]

Research C for DE and. FDA D.I.S.C.O, 2024, Burst Edition: FDA approvals of Opdualag (nivolumab and relatlimab-rmbw) for unresectable or metastatic melanoma, and Keytruda (pembrolizumab) for patients with advanced endometrial carcinoma

[54] Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer [J].

Reuss, Joshua E. ;

Anagnostou, Valsamo ;

Cottrell, Tricia R. ;

Smith, Kellie N. ;

Verde, Franco ;

Zahurak, Marianna ;

Lanis, Mara ;

Murray, Joseph C. ;

Chan, Hok Yee ;

McCarthy, Caroline ;

Wang, Daphne ;

White, James R. ;

Yang, Stephen ;

Battafarano, Richard ;

Broderick, Stephen ;

Bush, Errol ;

Brock, Malcolm ;

Ha, Jinny ;

Jones, David ;

Merghoub, Taha ;

Taube, Janis ;

Velculescu, Victor E. ;

Rosner, Gary ;

Illei, Peter ;

Pardoll, Drew M. ;

Topalian, Suzanne ;

Naidoo, Jarushka ;

Levy, Ben ;

Hellmann, Matthew ;

Brahmer, Julie R. ;

Chaft, Jamie E. ;

Forde, Patrick M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[55] Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status [J].

Ricciuti, Biagio ;

Arbour, Kathryn C. ;

Lin, Jessica J. ;

Vajdi, Amir ;

Vokes, Natalie ;

Hong, Lingzhi ;

Zhang, Jianjun ;

Tolstorukov, Michael Y. ;

Li, Yvonne Y. ;

Spurr, Liam F. ;

Cherniack, Andrew D. ;

Recondo, Gonzalo ;

Lamberti, Giuseppe ;

Wang, Xinan ;

Venkatraman, Deepti ;

Alessi, Joao, V ;

Vaz, Victor R. ;

Rizvi, Hira ;

Egger, Jacklynn ;

Plodkowski, Andrew J. ;

Khosrowjerdi, Sara ;

Digumarthy, Subba ;

Park, Hyesun ;

Vaz, Nuno ;

Nishino, Mizuki ;

Sholl, Lynette M. ;

Barbie, David ;

Altan, Mehmet ;

Heymach, John, V ;

Skoulidis, Ferdinandos ;

Gainor, Justin F. ;

Hellmann, Matthew D. ;

Awad, Mark M. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) :399-410

[56] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial [J].

Rothschild, Sacha, I ;

Zippelius, Alfred ;

Eboulet, Eric, I ;

Prince, Spasenija Savic ;

Betticher, Daniel ;

Bettini, Adrienne ;

Frueh, Martin ;

Joerger, Markus ;

Lardinois, Didier ;

Gelpke, Hans ;

Mauti, Laetitia A. ;

Britschgi, Christian ;

Weder, Walter ;

Peters, Solange ;

Mark, Michael ;

Cathomas, Richard ;

Ochsenbein, Adrian F. ;

Janthur, Wolf-Dieter ;

Waibel, Christine ;

Mach, Nicolas ;

Froesch, Patrizia ;

Buess, Martin ;

Bohanes, Pierre ;

Godar, Gilles ;

Rusterholz, Corinne ;

Gonzalez, Michel ;

Pless, Miklos .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) :2872-+

[57] Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas [J].

Schoenfeld, A. J. ;

Rizvi, H. ;

Bandlamudi, C. ;

Sauter, J. L. ;

Travis, W. D. ;

Rekhtman, N. ;

Plodkowski, A. J. ;

Perez-Johnston, R. ;

Sawan, P. ;

Beras, A. ;

Egger, J. V. ;

Ladanyi, M. ;

Arbour, K. C. ;

Rudin, C. M. ;

Riely, G. J. ;

Taylor, B. S. ;

Donoghue, M. T. A. ;

Hellmann, M. D. .

ANNALS OF ONCOLOGY, 2020, 31 (05) :599-608

[58] Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial [J].

Schuler, Martin ;

Cuppens, Kristof ;

Ploenes, Till ;

Wiesweg, Marcel ;

Du Pont, Bert ;

Hegedus, Balazs ;

Koester, Johannes ;

Mairinger, Fabian ;

Darwiche, Kaid ;

Paschen, Annette ;

Maes, Brigitte ;

Vanbockrijck, Michel ;

Laehnemann, David ;

Zhao, Fang ;

Hautzel, Hubertus ;

Theegarten, Dirk ;

Hartemink, Koen ;

Reis, Henning ;

Baas, Paul ;

Schramm, Alexander ;

Aigner, Clemens .

NATURE MEDICINE, 2024, 30 (06) :1602-1611

[59] Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy [J].

Shan, Jianzhen ;

Liu, Zhen ;

Chen, Songan ;

Du, Chengli ;

Li, Bing ;

Ruan, Lingxiang ;

Kong, Mei ;

Wang, Lingjie ;

Du, Miaoyan ;

Shi, Shuo ;

Qiao, Guoliang ;

Tian, Tian ;

Tu, Zhengliang .

BMC MEDICINE, 2024, 22 (01)

[60] Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050 [J].

Sharma, Rajesh .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (04) :665-675

← 1 2 3 4 5 6 7 8 9 →